tirzepatide palpitations and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism Life-Threatening Ventricular Fibrillation Linked to
Description
GLP-1 medications begin working immediately with most patients seeing steady weight loss over time
In studies involving patients with overweight or obesity, participants experienced an average weight loss of 5.9% after 3 months and 10.9% after 6 months
These can cause spikes in your blood sugar, counteracting the benefits of the medication
More variables to manage
Int J Obes 40(8):1310
Pancreatitis: WeGovy may raise pancreatitis risk
